Brief: Alzamend Neuro Announces Positive Topline Data From Phase 1 First-In-Human Clinical Trial For AL001 Treatment Of Dementia Related To Alzheimer's

Alzamend Neuro

17/12/2021 14:06

Dec 17 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE
1
FIRST-IN-HUMAN CLINICAL TRIAL FOR AL001 TREATMENT OF DEMENTIA
RELATED TO ALZHEIMER'S
    * ALZAMEND NEURO - LOOK FORWARD TO INITIATING PHASE 2
MULTIPLE
ASCENDING DOSE STUDY INVOLVING ALZHEIMER'S PATIENTS IN Q2 OF
2022
    * ALZAMEND NEURO - PURSUING IND APPLICATIONS WITH U.S. FDA
DURING
2022 FOR BIPOLAR DISORDER, DEPRESSION, & POST-TRAUMATIC STRESS
DISORDER INDICATION

Source text for Eikon:  ID:nBwbdxpj4a 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))